1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 3,580 | 3,820 | 28.08. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 19.08. | Clene: Zulassungspfad für ALS-Medikament bei der FDA nimmt Gestalt an | 1 | Investing.com Deutsch | ||
| CLENE Aktie jetzt für 0€ handeln | |||||
| 14.08. | Clene GAAP EPS of -$1.08 misses by $0.71 | 2 | Seeking Alpha | ||
| 14.08. | Clene Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 10.08. | Clene meldet Überlebensvorteil bei ALS-Patienten mit NfL-Biomarker-Ansprechen | 4 | Investing.com Deutsch | ||
| 10.08. | Clene reports survival benefit in ALS patients with NfL response | 1 | Investing.com | ||
| 10.08. | Clene Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 05.06. | Clene Inc. - S-8, Securities to be offered to employees in employee benefit plans | 2 | SEC Filings | ||
| 04.06. | Clene (CLNN) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now | 7 | Zacks | ||
| 22.05. | Clene Inc. - 8-K, Current Report | 3 | SEC Filings | ||
| 14.05. | Clene GAAP EPS of -$0.69, revenue of $0.01M | 2 | Seeking Alpha | ||
| 14.05. | Clene Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 14.05. | Clene Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 05.05. | Clene Inc.: Clene Announces $7 Million Underwritten Offering of Common Stock | 4 | GlobeNewswire (USA) | ||
| 04.05. | Clene Stock Jumps After FDA Opens Door To Accelerated Approval For ALS Drug | 5 | Benzinga.com | ||
| 04.05. | Clene plans ALS drug application after FDA meeting | 4 | Investing.com | ||
| 04.05. | Clene-Aktie legt um 20 % zu: FDA stellt beschleunigte Zulassung für ALS-Medikament in Aussicht | 12 | Investing.com Deutsch | ||
| 04.05. | Clene Inc. - 8-K, Current Report | - | SEC Filings | ||
| 17.03. | Clene Inc. - 10-K, Annual Report | 2 | SEC Filings | ||
| 12.03. | Clene GAAP EPS of -$2.65, revenue of $0.2M | 3 | Seeking Alpha | ||
| 12.03. | Clene Inc. - 8-K, Current Report | - | SEC Filings |
1 2 Weiter >>
22 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 88,30 | +0,11 % | BioNTech Aktie: Im Rausch der Moderna-Euphorie - Doch wie lange hält die Party an? | © Foto: von fernando zhiminaicela auf Pixabay (Symbolbild)Fast 30 Prozent in einer einzigen Woche. Das ist lange her, dass sowas bei BioNTech vorkam. Zuletzt wohl zu Pandemie-Zeiten ging es mal so zur... ► Artikel lesen | |
| MEDIGENE | 0,006 | 0,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 30.06.2026 | The following instruments on Boerse Frankfurt do have their last trading day on 30.06.2026Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 30.06.2026ISIN NameBE0003593044 COFINIMMOCA8765111064 TASEKO... ► Artikel lesen | |
| AMGEN | 371,90 | -0,35 % | Amgen: Tezspire Demonstrates Positive Phase 3 Results In Eosinophilic Esophagitis Across Both Co-primary And All Key Secondary Endpoints | Statistically Significant and Clinically Meaningful Disease and Symptom Improvements Compared to Placebo Maintained Through Week 52
Efficacy in a Third Epithelial-Driven... ► Artikel lesen | |
| NOVAVAX | 7,950 | -0,62 % | Novavax announces regulatory approvals for updated COVID shot | ||
| BIOGEN | 187,62 | -0,51 % | Veeva Systems: Veeva Vault CRM Selected by Biogen | Unified commercial platform to help speed the delivery of medicines to patientsPLEASANTON, Calif., Aug. 25, 2026 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced that Biogen has... ► Artikel lesen | |
| BIOFRONTERA | 2,500 | +2,46 % | PTA-Adhoc: Biofrontera AG: Biofrontera AG beschließt Vorbereitung des Wechsels vom regulierten Markt (Prime Standard) in das Börsensegment Scale | DJ PTA-Adhoc: Biofrontera AG: Biofrontera AG beschließt Vorbereitung des Wechsels vom regulierten Markt (Prime Standard) in das Börsensegment Scale
Veröffentlichung von Insiderinformationen gemäß... ► Artikel lesen | |
| ILLUMINA | 186,64 | +0,27 % | $100 Invested In Illumina 20 Years Ago Would Be Worth This Much Today | ||
| CRISPR THERAPEUTICS | 49,360 | -0,85 % | CRISPR Therapeutics legt positive Einjahresdaten für Gentherapie CTX310 vor | ||
| PALATIN TECHNOLOGIES | 10,500 | +0,19 % | Wall Street Wire: StreetWatch: A $2.9 Billion Takeover Put a Spotlight on Relentless Hunger. Palatin Technologies Is Developing the Next Generation of the Drug That Seeks to Treat It | Rare-endocrine buyers have paid roughly $2.9 billion and approximately $10.0 billion for acquisitions in this area over the past four months. IMCIVREE, the only approved MC4R agonist for acquired... ► Artikel lesen | |
| INOVIO PHARMACEUTICALS | 1,070 | -3,60 % | INOVIO Pharmaceuticals, Inc.: INOVIO Reports Second Quarter 2026 Financial Results and Recent Business Highlights | U.S. Food and Drug Administration (FDA) review of Biologics License Application (BLA) for INO-3107 as a treatment for Recurrent Respiratory Papillomatosis (RRP)... ► Artikel lesen | |
| CLINUVEL | 5,318 | -0,26 % | Clinuvel Pharmaceuticals Ltd - 6-K, Report of foreign issuer | ||
| SANGAMO THERAPEUTICS | 0,126 | -100,00 % | Sangamo Therapeutics, Inc.: Sangamo Therapeutics Selects Successful Bidders Following Competitive Asset Auction for $163.55 Million in Cash Consideration at Closing and Up to $100 Million in Potential Milestones | PTC Therapeutics to purchase Fabry disease program, isaralgagene civaparvovec Lilly to purchase capsid delivery, zinc finger and modular integrase (MINT) platforms and prion disease program Proposed... ► Artikel lesen | |
| VIKING THERAPEUTICS | 27,850 | +0,36 % | Viking Therapeutics Has $502 Million in Cash and 1 Big Catalyst Left in 2026 -- Is That Enough? | ||
| INTELLIA THERAPEUTICS | 11,220 | +0,90 % | Cathie Wood's ARK buys Intellia stock, sells Roblox | ||
| TEMPUS AI | 55,25 | -0,04 % | Tempus AI (TEM) Jumped on Moderna's Melanoma Win. Did its $1.5B Personalis Acquisition Just Get Validated? |
Das Unternehmen CLENE INC kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 3,840 Euro und damit +3,78 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu CLENE INC finden Sie auf Wallstreet Online.